Ansa Biotechnologies

The company is developing a proprietary platform to produce DNA with greater speed, accuracy, and scalability compared to conventional chemical methods, aiming to meet the growing demand for high-quality DNA in cell and gene therapy development.

In October 2025, Ansa announced the close of an oversubscribed $54.4 million Series B financing. The round included a $45.2 million initial tranche with commitments for an additional $9.2 million, providing the company with capital to expand manufacturing capacity, accelerate product development, and support commercial readiness.

While Ansa is not advancing therapeutic candidates directly, its platform is positioned as an enabling technology for biotech and pharmaceutical companies working in RNA, DNA, and cell-based therapies. By improving access to complex synthetic DNA constructs, Ansa aims to play a critical role in supporting clinical development pipelines across the sector.